Copyright Reports & Markets. All rights reserved.

Global Biosimilar Monoclonal Antibodies Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Biosimilar Monoclonal Antibodies Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Infliximab
    • 1.3.3 Rituximab
    • 1.3.4 Trastuzumab
    • 1.3.5 Adalimumab
    • 1.3.6 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Biosimilar Monoclonal Antibodies Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Oncology
    • 1.4.3 Autoimmune Disease
    • 1.4.4 Other
  • 1.5 Global Biosimilar Monoclonal Antibodies Market Size & Forecast
    • 1.5.1 Global Biosimilar Monoclonal Antibodies Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Biosimilar Monoclonal Antibodies Sales Quantity (2021-2032)
    • 1.5.3 Global Biosimilar Monoclonal Antibodies Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Celltrion
    • 2.1.1 Celltrion Details
    • 2.1.2 Celltrion Major Business
    • 2.1.3 Celltrion Biosimilar Monoclonal Antibodies Product and Services
    • 2.1.4 Celltrion Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Celltrion Recent Developments/Updates
  • 2.2 Pfizer (Hospira)
    • 2.2.1 Pfizer (Hospira) Details
    • 2.2.2 Pfizer (Hospira) Major Business
    • 2.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product and Services
    • 2.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Pfizer (Hospira) Recent Developments/Updates
  • 2.3 3SBIO
    • 2.3.1 3SBIO Details
    • 2.3.2 3SBIO Major Business
    • 2.3.3 3SBIO Biosimilar Monoclonal Antibodies Product and Services
    • 2.3.4 3SBIO Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 3SBIO Recent Developments/Updates
  • 2.4 Novartis (Sandoz)
    • 2.4.1 Novartis (Sandoz) Details
    • 2.4.2 Novartis (Sandoz) Major Business
    • 2.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product and Services
    • 2.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Novartis (Sandoz) Recent Developments/Updates
  • 2.5 Dr Reddy’s
    • 2.5.1 Dr Reddy’s Details
    • 2.5.2 Dr Reddy’s Major Business
    • 2.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Product and Services
    • 2.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Dr Reddy’s Recent Developments/Updates
  • 2.6 Celgen Biopharma
    • 2.6.1 Celgen Biopharma Details
    • 2.6.2 Celgen Biopharma Major Business
    • 2.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Product and Services
    • 2.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Celgen Biopharma Recent Developments/Updates
  • 2.7 Cadila Healthcare
    • 2.7.1 Cadila Healthcare Details
    • 2.7.2 Cadila Healthcare Major Business
    • 2.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Product and Services
    • 2.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Cadila Healthcare Recent Developments/Updates
  • 2.8 Hisun Pharma
    • 2.8.1 Hisun Pharma Details
    • 2.8.2 Hisun Pharma Major Business
    • 2.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Product and Services
    • 2.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Hisun Pharma Recent Developments/Updates
  • 2.9 Torrent Pharmaceuticals
    • 2.9.1 Torrent Pharmaceuticals Details
    • 2.9.2 Torrent Pharmaceuticals Major Business
    • 2.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product and Services
    • 2.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Torrent Pharmaceuticals Recent Developments/Updates
  • 2.10 Fresenius Kabi
    • 2.10.1 Fresenius Kabi Details
    • 2.10.2 Fresenius Kabi Major Business
    • 2.10.3 Fresenius Kabi Biosimilar Monoclonal Antibodies Product and Services
    • 2.10.4 Fresenius Kabi Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Fresenius Kabi Recent Developments/Updates
  • 2.11 Coherus Solutions
    • 2.11.1 Coherus Solutions Details
    • 2.11.2 Coherus Solutions Major Business
    • 2.11.3 Coherus Solutions Biosimilar Monoclonal Antibodies Product and Services
    • 2.11.4 Coherus Solutions Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Coherus Solutions Recent Developments/Updates
  • 2.12 Biogen
    • 2.12.1 Biogen Details
    • 2.12.2 Biogen Major Business
    • 2.12.3 Biogen Biosimilar Monoclonal Antibodies Product and Services
    • 2.12.4 Biogen Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Biogen Recent Developments/Updates
  • 2.13 Amgen
    • 2.13.1 Amgen Details
    • 2.13.2 Amgen Major Business
    • 2.13.3 Amgen Biosimilar Monoclonal Antibodies Product and Services
    • 2.13.4 Amgen Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Amgen Recent Developments/Updates
  • 2.14 Biocon Biologics
    • 2.14.1 Biocon Biologics Details
    • 2.14.2 Biocon Biologics Major Business
    • 2.14.3 Biocon Biologics Biosimilar Monoclonal Antibodies Product and Services
    • 2.14.4 Biocon Biologics Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Biocon Biologics Recent Developments/Updates
  • 2.15 Organon
    • 2.15.1 Organon Details
    • 2.15.2 Organon Major Business
    • 2.15.3 Organon Biosimilar Monoclonal Antibodies Product and Services
    • 2.15.4 Organon Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Organon Recent Developments/Updates

3 Competitive Environment: Biosimilar Monoclonal Antibodies by Manufacturer

  • 3.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Biosimilar Monoclonal Antibodies Revenue by Manufacturer (2021-2026)
  • 3.3 Global Biosimilar Monoclonal Antibodies Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Biosimilar Monoclonal Antibodies by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Biosimilar Monoclonal Antibodies Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Biosimilar Monoclonal Antibodies Manufacturer Market Share in 2025
  • 3.5 Biosimilar Monoclonal Antibodies Market: Overall Company Footprint Analysis
    • 3.5.1 Biosimilar Monoclonal Antibodies Market: Region Footprint
    • 3.5.2 Biosimilar Monoclonal Antibodies Market: Company Product Type Footprint
    • 3.5.3 Biosimilar Monoclonal Antibodies Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Biosimilar Monoclonal Antibodies Market Size by Region
    • 4.1.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Biosimilar Monoclonal Antibodies Consumption Value by Region (2021-2032)
    • 4.1.3 Global Biosimilar Monoclonal Antibodies Average Price by Region (2021-2032)
  • 4.2 North America Biosimilar Monoclonal Antibodies Consumption Value (2021-2032)
  • 4.3 Europe Biosimilar Monoclonal Antibodies Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value (2021-2032)
  • 4.5 South America Biosimilar Monoclonal Antibodies Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Type (2021-2032)
  • 5.2 Global Biosimilar Monoclonal Antibodies Consumption Value by Type (2021-2032)
  • 5.3 Global Biosimilar Monoclonal Antibodies Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Application (2021-2032)
  • 6.2 Global Biosimilar Monoclonal Antibodies Consumption Value by Application (2021-2032)
  • 6.3 Global Biosimilar Monoclonal Antibodies Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Biosimilar Monoclonal Antibodies Sales Quantity by Type (2021-2032)
  • 7.2 North America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2021-2032)
  • 7.3 North America Biosimilar Monoclonal Antibodies Market Size by Country
    • 7.3.1 North America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Biosimilar Monoclonal Antibodies Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Biosimilar Monoclonal Antibodies Sales Quantity by Type (2021-2032)
  • 8.2 Europe Biosimilar Monoclonal Antibodies Sales Quantity by Application (2021-2032)
  • 8.3 Europe Biosimilar Monoclonal Antibodies Market Size by Country
    • 8.3.1 Europe Biosimilar Monoclonal Antibodies Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Biosimilar Monoclonal Antibodies Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Biosimilar Monoclonal Antibodies Market Size by Region
    • 9.3.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Biosimilar Monoclonal Antibodies Sales Quantity by Type (2021-2032)
  • 10.2 South America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2021-2032)
  • 10.3 South America Biosimilar Monoclonal Antibodies Market Size by Country
    • 10.3.1 South America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Biosimilar Monoclonal Antibodies Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Biosimilar Monoclonal Antibodies Market Size by Country
    • 11.3.1 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Biosimilar Monoclonal Antibodies Market Drivers
  • 12.2 Biosimilar Monoclonal Antibodies Market Restraints
  • 12.3 Biosimilar Monoclonal Antibodies Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Biosimilar Monoclonal Antibodies and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Biosimilar Monoclonal Antibodies
  • 13.3 Biosimilar Monoclonal Antibodies Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Biosimilar Monoclonal Antibodies Typical Distributors
  • 14.3 Biosimilar Monoclonal Antibodies Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Biosimilar Monoclonal Antibodies market size was valued at US$ 7165 million in 2025 and is forecast to a readjusted size of US$ 19590 million by 2032 with a CAGR of 15.6% during review period.
    Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies. Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
    The biosimilar monoclonal antibodies market is primarily driven by the increasing demand for cost-effective biologic treatments. As patents for many original biologic drugs expire, biosimilars offer a more affordable alternative without compromising efficacy. This is particularly important in treating chronic diseases like cancer and autoimmune disorders, where long-term treatment costs can be prohibitive. The growing acceptance of biosimilars by healthcare providers and regulatory approvals in various regions further propels market growth. However, a key challenge facing the market is the complexity of manufacturing biosimilar monoclonal antibodies. Due to their structural intricacies, even minor variations in production processes can lead to differences in efficacy or safety compared to the original biologic. Additionally, patient and physician skepticism, driven by concerns over efficacy and potential side effects, can hinder widespread adoption, especially in markets where the original biologics are well-established. Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis, etc. Global top four manufacturers hold a share nearly 85%. Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent. In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.
    This report is a detailed and comprehensive analysis for global Biosimilar Monoclonal Antibodies market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Biosimilar Monoclonal Antibodies market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Biosimilar Monoclonal Antibodies market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Biosimilar Monoclonal Antibodies market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Biosimilar Monoclonal Antibodies market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Biosimilar Monoclonal Antibodies
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Biosimilar Monoclonal Antibodies market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Celltrion, Pfizer (Hospira), 3SBIO, Novartis (Sandoz), Dr Reddy’s, Celgen Biopharma, Cadila Healthcare, Hisun Pharma, Torrent Pharmaceuticals, Fresenius Kabi, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Biosimilar Monoclonal Antibodies market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Infliximab
    Rituximab
    Trastuzumab
    Adalimumab
    Other
    Market segment by Application
    Oncology
    Autoimmune Disease
    Other
    Major players covered
    Celltrion
    Pfizer (Hospira)
    3SBIO
    Novartis (Sandoz)
    Dr Reddy’s
    Celgen Biopharma
    Cadila Healthcare
    Hisun Pharma
    Torrent Pharmaceuticals
    Fresenius Kabi
    Coherus Solutions
    Biogen
    Amgen
    Biocon Biologics
    Organon
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Biosimilar Monoclonal Antibodies product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Biosimilar Monoclonal Antibodies, with price, sales quantity, revenue, and global market share of Biosimilar Monoclonal Antibodies from 2021 to 2026.
    Chapter 3, the Biosimilar Monoclonal Antibodies competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Biosimilar Monoclonal Antibodies breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Biosimilar Monoclonal Antibodies market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Biosimilar Monoclonal Antibodies.
    Chapter 14 and 15, to describe Biosimilar Monoclonal Antibodies sales channel, distributors, customers, research findings and conclusion.

    Buy now